Rituximab may affect T lymphocyte subsets balance in primary membranous nephropathy

被引:1
|
作者
Zhang, Yuanyuan [1 ,2 ]
Yang, Jingjing [3 ]
Li, Jianzhong [1 ]
Sun, Jiani [1 ]
Zhou, Ling [1 ]
Xu, Deyu [1 ]
Sha, Wengang [1 ]
Dai, Lan [4 ]
Shen, Lei [1 ]
机构
[1] Soochow Univ, Dept Nephrol, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Nanjing Univ, Suzhou Hosp, Affiliated Hosp, Dept Nephrol,Med Sch, Suzhou, Peoples R China
[3] BenQ Med Ctr, Dept Nephrol, Suzhou, Peoples R China
[4] Soochow Univ, Jiangsu Inst Hematol, Minist Hlth, Key Lab Thrombosis & Hemostasis,Affiliated Hosp 1, Suzhou, Peoples R China
关键词
Rituximab; Primary membranous nephropathy; T lymphocyte subsets; B lymphocyte cells; Anti-PLA2R antibody; RECEPTOR; CHILDREN; CELLS;
D O I
10.1186/s12882-024-03521-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe aim of this study was to investigate the effects and significance of rituximab (RTX) on the levels of T lymphocyte subsets in patients diagnosed with primary membranous nephropathy (PMN).MethodsA total of 58 PMN patients and 25 healthy donors were chosen as the subjects. Among the PMN patients, 40 individuals received RTX treatment and completed at least 6 months of follow-up. All subjects underwent flow cytometry analysis to determine the peripheral blood lymphocyte subsets. The changes in anti-PLA2R antibody titers and 24-hour urinary protein levels were evaluated by ELISA and Biuret method before and after treatment.Results(1) The PMN group exhibited a significantly greater percentage of peripheral blood CD3-CD19+ B cells than the healthy group, which is consistent with the findings of previous reports. Additionally, compared with those in the peripheral blood of healthy individuals, the numbers of CD4+ central memory T cells, CD4+ effector memory T cells, CD4+/CD8+, and CD4+CD25+ T cells in the PMN peripheral blood were markedly greater. However, the number of peripheral blood Treg cells was reduced in the PMN group. (2) After 6 months of RTX treatment, PMN patients exhibited significant decreases in anti-PLA2R antibody titers, 24-hour urinary protein levels, and peripheral blood CD3-CD19+ B cells. Importantly, RTX administration decreased CD4+CD25+ T cells and CD4+/CD8+ in the peripheral blood of PMN patients and improved Treg cell levels. (3) RTX treatment induced alterations in the CD4+ T lymphocyte subsets in PMN patients, which did not correlate with B lymphocyte counts or anti-PLA2R antibody titers.ConclusionsRTX treatment might have a beneficial impact on cellular immunity by effectively restoring the balance of CD4+ T lymphocyte subsets in PMN patients, which is beyond its effects on B cells and antibody production.Trial registrationThe research was registered at the First Affiliated Hospital of Soochow University. Registration Number: MR-32-23-016211. Registration Date: May 31, 2023.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Low-dose Rituximab Monotherapy or in Combination with Tacrolimus Is Effective in Primary Membranous Nephropathy
    Pathak, Vivek
    Venkatesan, Madhav
    Regunathan-Shenk, Renu
    KIDNEY360, 2021, 2 (02): : 336 - 338
  • [32] A Study Comparing Rituximab and Modified Ponticelli (MP) Regimen in Primary Membranous Nephropathy(PMN)
    Kumar, Abhishek
    Chaudhury, Arpita Ray
    Gupta, Saugat D.
    Mukherjee, Sriranjan
    Sengupta, Moumita
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 513 - 513
  • [33] Efficacy analysis of rituximab in treating patients with primary membranous nephropathy dependent on calcineurin inhibitors
    Li, Zhuo
    Zhao, Tingting
    Zhang, Shasha
    Huang, Jing
    Wang, Honggang
    Sun, Yujiao
    Wang, Rong
    Chen, Bing
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [34] T-LYMPHOCYTE SUBSETS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME
    PAPO, T
    PIETTE, JC
    LEGAC, E
    FRANCES, C
    GRENOT, P
    DEBRE, P
    GODEAU, P
    AUTRAN, B
    JOURNAL OF RHEUMATOLOGY, 1994, 21 (12) : 2242 - 2245
  • [35] LYMPHOCYTE-T SUBSETS IN PRIMARY AND SECONDARY GLOMERULONEPHRITIDES
    FORNASIERI, A
    SINICO, R
    FIORINI, G
    GOLDANIGA, D
    COLASANTI, G
    VENDEMIA, F
    GIBELLI, A
    DAMICO, G
    KIDNEY INTERNATIONAL, 1983, 23 (03) : 553 - 553
  • [36] LYMPHOCYTE-T SUBSETS IN PRIMARY AND SECONDARY GLOMERULONEPHRITIS
    FORNASIERI, A
    SINICO, R
    FIORINI, G
    GOLDANIGA, D
    COLASANTI, G
    VENDEMIA, F
    GIBELLI, A
    DAMICO, G
    PROCEEDINGS OF THE EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION, 1982, 19 : 635 - 641
  • [37] PROGNOSTIC VALUE OF LYMPHOCYTE-T SUBSET RATIO IN IDIOPATHIC MEMBRANOUS NEPHROPATHY
    ZUCCHELLI, P
    PONTICELLI, C
    CAGNOLI, L
    AROLDI, A
    BELTRANDI, E
    AMERICAN JOURNAL OF NEPHROLOGY, 1988, 8 (01) : 15 - 20
  • [38] Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model
    Hamilton, Patrick
    Kanigicherla, Durga
    Venning, Michael
    Brenchley, Paul
    Meads, David
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 (12) : 2145 - 2155
  • [39] Plasma exchange and rituximab treatments in primary membranous nephropathy combined with crescentic glomerulonephritis A case report
    Lu, Hui
    Cui, Zhao
    Zhou, Xu-jie
    Jin, Qi-zhuang
    Yu, Xiao-juan
    Wang, Su-xia
    Wang, Yu
    Zhou, Fu-de
    Zhao, Ming-hui
    MEDICINE, 2019, 98 (18)
  • [40] LYMPHOCYTE-T SUBSETS IN PRIMARY LUNG-CANCER
    TSUYUGUCHI, I
    SHIRATSUCHI, H
    FUKUOKA, M
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1987, 17 (01) : 13 - 17